Stay updated on Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.

Latest updates to the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page
- Check6 days agoChange DetectedRemoval of the Melanoma term, the related topics header, and the MedlinePlus Genetics link from the study details page. These changes alter the page’s disease context and access to related educational resources.SummaryDifference0.1%

- Check13 days agoChange DetectedThe study page now states that recruitment is closed. It also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment heading along with a Revision: v3.6.0 tag.SummaryDifference0.3%

- Check21 days agoChange DetectedThe page revision tag was updated from Revision: v3.5.4 to Revision: v3.5.5, indicating a newer patch of the documentation.SummaryDifference0.0%

- Check29 days agoChange DetectedMelanoma condition listing and the MedlinePlus Genetics related topics block were removed. This reduces visible disease context and related educational links on the page.SummaryDifference0.1%

- Check43 days agoChange DetectedMelanoma is added as a related topic and MedlinePlus Genetics is listed as a related resource, and the page revision has been updated from v3.5.3 to v3.5.4.SummaryDifference0.1%

- Check65 days agoChange DetectedThe page’s UI/version footer was updated from “Revision: v3.5.0” to “Revision: v3.5.3,” reflecting an underlying change to the ClinicalTrials.gov site build rather than any content about the study.SummaryDifference0.0%

Stay in the know with updates to Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.